For example, the expression of PD-L1 has been associated with beneficial responses to PD-1/PD-L1 blockade across multiple cancer types; however, other studies demonstrated that patients with PD-L1 negative tumors can still achieve favorable outcomes when treated with PD-1/PD-L1 inhibitors (180–183). This evidence concerns the gene CD274 and cancer.